United Services Automobile Association lowered its position in Johnson & Johnson (NYSE:JNJ) by 29.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 423,820 shares of the company’s stock after selling 177,889 shares during the period. Johnson & Johnson comprises about 0.7% of United Services Automobile Association’s portfolio, making the stock its 27th largest position. United Services Automobile Association’s holdings in Johnson & Johnson were worth $61,790,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Aries Wealth Management raised its position in shares of Johnson & Johnson by 0.3% in the fourth quarter. Aries Wealth Management now owns 27,932 shares of the company’s stock valued at $4,025,000 after purchasing an additional 75 shares during the period. Portland Global Advisors LLC grew its stake in Johnson & Johnson by 0.9% in the 3rd quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock valued at $1,131,000 after buying an additional 78 shares in the last quarter. SRS Capital Advisors Inc. raised its holdings in Johnson & Johnson by 0.5% during the 3rd quarter. SRS Capital Advisors Inc. now owns 17,452 shares of the company’s stock valued at $2,258,000 after acquiring an additional 79 shares during the period. Alta Capital Management LLC raised its holdings in Johnson & Johnson by 3.9% during the 3rd quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock valued at $282,000 after acquiring an additional 82 shares during the period. Finally, G&S Capital LLC lifted its position in shares of Johnson & Johnson by 1.8% during the third quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock worth $604,000 after acquiring an additional 84 shares in the last quarter. 67.28% of the stock is currently owned by institutional investors.
JNJ has been the subject of a number of analyst reports. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Friday, October 11th. Credit Suisse Group reiterated a “buy” rating and set a $163.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, December 31st. Barclays raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $140.00 to $173.00 in a report on Thursday, December 19th. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price for the company in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $159.33.
JNJ opened at $146.52 on Wednesday. The firm has a market capitalization of $381.78 billion, a P/E ratio of 17.91, a price-to-earnings-growth ratio of 2.33 and a beta of 0.71. Johnson & Johnson has a one year low of $125.00 and a one year high of $147.84. The company has a fifty day moving average price of $142.86 and a 200-day moving average price of $134.74. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. During the same quarter last year, the business posted $2.05 earnings per share. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 8.66 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.59%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s payout ratio is 46.45%.
In other Johnson & Johnson news, Director Hubert Joly acquired 5,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $141.28 per share, with a total value of $706,400.00. Following the completion of the acquisition, the director now owns 5,000 shares of the company’s stock, valued at $706,400. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 2,017 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $141.07, for a total value of $284,538.19. Following the transaction, the executive vice president now directly owns 51,736 shares of the company’s stock, valued at approximately $7,298,397.52. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Understanding Market Liquidity
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.